Transgene Biotek is currently trading at Rs. 10.50, up by 0.26 points or 2.54% from its previous closing of Rs. 10.24 on the BSE.
The scrip opened at Rs. 10.64 and has touched a high and low of Rs. 10.64 and Rs. 10.41 respectively. So far 190069 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 62.50 on 16-Nov-2011 and a 52 week low of Rs. 8.95 on 13-Aug-2012.
Last one week high and low of the scrip stood at Rs. 11.74 and Rs. 10.22 respectively. The current market cap of the company is Rs. 69.58 crore.
The promoters holding in the company stood at 9.78% while Institutions and Non-Institutions held 1.86% and 14.92% respectively.
Mauritius-based Stream Value Fund has agreed to join hands with Transgene Biotek, a pharmaceutical company. It will join the company on a long-term basis to support its drug discovery activity, in return for equity participation and certain rewards on drug licensing or sale.
The Mauritius Fund, which invests in CSR and sustainable finance initiatives in Asia, Africa, etc, is a registered FII with the SEBI.
Recently, the Transgene Biotek sold undisclosed quantum of stake to a foreign institutional investor as a result of which the company's shares will be delisted from domestic stock exchanges. Further, the company is in the process of sending the postal ballot to all its shareholders seeking their approval.
Transgene Biotek, is a biotechnology company. It is involved in the development of several cutting edge technologies.
Company Name | CMP |
---|---|
Apollo Hospital Ent. | 7036.65 |
Max Healthcare Inst | 1006.75 |
Narayana Hrudayalay | 1249.35 |
Aster DM Healthcare | 444.55 |
Global Health | 1115.50 |
View more.. |